Application Detail
Status
OpenDescription of Medical Service
Oncotype DX® is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.Description of Medical Condition
Outside Australia, Oncotype DX® is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.Reason for Application
Re-submissionMedical Service Type
InvestigativePrevious Application Numbers
13421342.1
1342.2
1342.3
1342.4
Associated Documentation
Application Form
-Consultation Survey
Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1342.5 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).PICO Confirmation
As per application 1342Assessment Report
-Public Summary Document
Public Summary Document (PDF 1276 KB)Public Summary Document (Word 191 KB)